First Patient Enrolled in Phase II Clinical Trial of DECISION’s COMBAT Trial
• First patient enrolled at Hôpital Beaujon, Clichy, France • The COMBAT Trial is a multicenter, randomized, open-label, Phase II clinical trial in patients with decompensated cirrhosis Barcelona, Spain, 9th July 2024…
EASL announces JHEP Reports’ Impact Factor of 9.5 for 2023
The European Association for the Study of the Liver (EASL)is delighted to announce that JHEP Reports, its Open Access publication, achieved an impressive impact factor of 9.5 in the 2024 release of…
EASL announces Journal of Hepatology’s exceptional Impact Factor of 26.8 for 2023
The European Association for the Study of the Liver (EASL) is proud to announce that the Journal of Hepatology, its flagship publication, achieved an impact factor of 26.8 in the 2024 release…
New Editor-in-Chief for EASL’s Journal of Hepatology: Vlad Ratziu
The European Association for the Study of the Liver (EASL) is proud to announce the appointment of Prof. Vlad Ratziu as the new Editor-in-Chief of the Journal of Hepatology, the premier publication…
Launching the EASL Guidelines App!
Introducing the EASL Guidelines App – your indispensable mobile companion for accessing comprehensive and up-to-date clinical practice guidelines in hepatology. Developed by EASL, the European Association for the Study of the Liver,…
GENIAL: A pioneering initiative for early diagnosis of alcohol-related hepatocellular carcinoma
The GENIAL project is dedicated to enhancing our understanding of the early stages of alcohol-related hepatocellular carcinoma (ALD-HCC) by integrating clinical hepatology expertise with artificial intelligence (AI). This innovative initiative, as explained…
THRIVE related activities at EASL Congress 2024
THRIVE is an EU-founded initiative that brings together a strong and multidisciplinary team with 13 partners, from 8 countries, with complementary expertise in liver cancer research and in the use of cutting-edge…